Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine December 9, 2025 WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), is proud to recognize Curtis Patton, PhD, founding member of Tevogen’s Board ofContinue reading “Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine”
Press Release Archives
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook December 8, 2025 WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most influential organizations shaping New Jersey’sContinue reading “Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook”
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q November 14, 2025 WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a timeContinue reading “Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q”
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID November 5, 2025 WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced a clinical milestone in the evolution of its proprietary ExacTcell™ platform: completion of T cellContinue reading “Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID”
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn November 3, 2025 WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP accounting standards in recent SEC filings. GAAP rules areContinue reading “Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn”
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress October 29, 2025 WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma model centered on sustainability and patient affordability, highlighting the Company’s significantContinue reading “Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress”
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489 In recognition of the high volume of patient inquiries, Tevogen has established a dedicated communication channel for Long COVID updates at longCOVID@tevogen.comContinue reading “Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest”
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records. Potential future T cell therapies could reliably bind to their target nearly every time, dramaticallyContinue reading “Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion”
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID September 23, 2025 WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its investigational precision T cellContinue reading “Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID”
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans September 19, 2025 WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and theContinue reading “Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans”